NCT04335006 2023-05-06A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.Jiangsu HengRui Medicine Co., Ltd.Phase 3 Terminated80 enrolled